Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
3(25%)
Results Posted
43%(3 trials)

Phase Distribution

Ph phase_1
2
17%
Ph phase_2
4
33%
Ph phase_3
4
33%
Ph phase_4
1
8%
Ph early_phase_1
1
8%

Phase Distribution

3

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
4(33.3%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(7)
Terminated(2)

Detailed Status

Completed7
Recruiting3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 12 (16.7%)
Phase 24 (33.3%)
Phase 34 (33.3%)
Phase 41 (8.3%)

Trials by Status

withdrawn217%
completed758%
recruiting325%

Recent Activity

3 active trials
Showing 5 of 12
recruitingphase_1

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

NCT07083388
recruitingphase_1

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

NCT07083401
completedearly_phase_1

Pioglitazone for Idiopathic Gastroparesis

NCT04300127
recruitingphase_2

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

NCT05013255
completedphase_2

Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis

NCT05254626
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07083388Phase 1

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

Recruiting
NCT07083401Phase 1

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

Recruiting
NCT04300127Early Phase 1

Pioglitazone for Idiopathic Gastroparesis

Completed
NCT05013255Phase 2

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Recruiting
NCT05254626Phase 2

Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis

Completed
NCT05098327Phase 3

Pioglitazone and Insulin Resistance in ADT

Withdrawn
NCT04995978Phase 2

Insulin Resistance and Androgen Deprivation Therapy

Withdrawn
NCT04535700Phase 4

Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19

Completed
NCT04885712Phase 3

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Completed
NCT03125694Phase 3

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Completed
NCT01183013Phase 3

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Completed
NCT01230749Phase 2

A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12